Handok Asset Resilience Ratio
Handok asset resilience ratio. Handok (002390) has an Asset Resilience Ratio of 0.31% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 002390 defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Handok (2017–2025)
Asset resilience ratio of Handok from 2017 to 2025. This chart shows how Handok's Asset Resilience Ratio has changed over time. Read Handok (002390) financial obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Handok's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see 002390 current and non-current assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩2.50 Billion | 0.31% |
| Total Liquid Assets | ₩2.50 Billion | 0.31% |
Asset Resilience Insights
- Limited Liquidity: Handok maintains only 0.31% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Handok Industry Peers by Asset Resilience Ratio
Compare Handok's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262 |
Drug Manufacturers - Specialty & Generic | 26.45% |
|
Tibet Rhodiola Pharmaceutical Holding Co
SHG:600211 |
Drug Manufacturers - Specialty & Generic | 11.84% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Bide Pharmatech Co. Ltd. A
SHG:688073 |
Drug Manufacturers - Specialty & Generic | 9.46% |
|
Jianmin Pharmaceutical Group Co Ltd
SHG:600976 |
Drug Manufacturers - Specialty & Generic | 20.61% |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365 |
Drug Manufacturers - Specialty & Generic | 30.38% |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078 |
Drug Manufacturers - Specialty & Generic | 0.42% |
Handok Asset Resilience Ratio by Year (2017–2025)
Handok asset resilience ratio by year from 2017 to 2025. The table below shows the annual Asset Resilience Ratio data for Handok.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.38% | ₩3.00 Billion ≈ $2.03 Million |
₩790.75 Billion ≈ $535.88 Million |
0.00pp |
| 2024-12-31 | 0.38% | ₩3.00 Billion ≈ $2.03 Million |
₩788.56 Billion ≈ $534.39 Million |
-0.06pp |
| 2023-12-31 | 0.44% | ₩3.50 Billion ≈ $2.37 Million |
₩790.34 Billion ≈ $535.60 Million |
+0.10pp |
| 2022-12-31 | 0.34% | ₩3.00 Billion ≈ $2.03 Million |
₩871.11 Billion ≈ $590.34 Million |
-0.25pp |
| 2021-12-31 | 0.59% | ₩5.00 Billion ≈ $3.39 Million |
₩841.56 Billion ≈ $570.31 Million |
-0.63pp |
| 2020-12-31 | 1.22% | ₩10.00 Billion ≈ $6.78 Million |
₩818.93 Billion ≈ $554.97 Million |
-0.66pp |
| 2019-12-31 | 1.89% | ₩14.12 Billion ≈ $9.57 Million |
₩748.67 Billion ≈ $507.36 Million |
+1.49pp |
| 2018-12-31 | 0.40% | ₩2.61 Billion ≈ $1.77 Million |
₩652.62 Billion ≈ $442.27 Million |
+0.38pp |
| 2017-12-31 | 0.02% | ₩113.22 Million ≈ $76.73K |
₩639.35 Billion ≈ $433.28 Million |
-- |
About Handok
HANDOK Inc. operates as a pharmaceutical company. The company provides prescription and OTC drugs; medical devices, such as blood pressure monitors, cholesterol monitoring systems, insulin pumps, self-monitoring system of blood glucose, and blood glucose monitoring system; in vitro diagnostic medical devices; as well as life science products. It also offers healthcare products comprising food sup… Read more